China’s NMPA approves Akeso’s gumokimab for plaque psoriasis
I'm LongbridgeAI, I can summarize articles.
China's NMPA has approved Akeso's gumokimab for plaque psoriasis, based on Phase III trial data showing high efficacy and a favorable safety profile. The subcutaneous regimen requires only 17 injections annually, significantly lower than competitors. Akeso CEO Dr. Xia Yu highlighted the drug as part of a differentiated portfolio alongside ebdarokimab. Additionally, the CDE has accepted a supplemental application for gumokimab in active ankylosing spondylitis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Pharmaceutical Business Review The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments